Letter

Human papillomavirus vaccination

Glimpse into the black box of human papillomavirus vaccination

BMJ 2008; 337 doi: 10.1136/bmj.a1046 (Published 28 July 2008)
Cite this as: BMJ 2008;337:a1046

Access to the full text of this article requires a subscription or payment. Please log in or subscribe below.

  1. Peter M English, consultant in public health medicine1,
  2. Keith Neal, professor, epidemiology of infectious diseases, epidemiology and public health 2
  1. 1Surrey KT19 9XF
  2. 2University of Nottingham, NG7 2RH
  1. petermbenglish{at}gmail.com

    We welcome an opportunity to get a glimpse into the black box underlying the recent decisions about human papillomavirus (HPV) vaccination.1 We would like to reflect on the assumptions made. GlaxoSmithKline claims that Cervarix will provide protection longer, which would favour Cervarix. The paper by Jit et al does not reflect this (which is probably appropriate, since these claims are disputed).

    The paper’s assumption that those …

    Access to the full text of this article requires a subscription or payment

    Subscribe

    Article access

    Article access for 1 day

    Purchase this article for £20 $30 €32*

    The PDF version can be downloaded as your personal record

    * Prices do not include VAT

    Rapid responses

    THIS WEEK'S POLL

    BMJ most popular